RT Journal Article
T1 Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy
A1 Zaballos García, Matilde
A1 Power, Mercedes
A1 Canal Alonso, María Iluminada
A1 González Nicolás González, María Ángeles
A1 Vasquez Jimenez, Wenceslao
A1 Lozano Lominchar, Pablo
A1 Cabrerizo Torrente, Pilar
A1 Palencia García, Natividad
A1 Gago Quiroga, Susana
A1 Ginel Feito, María Dolores
A1 Jiménez, Consuelo
A1 Lázaro Fernández, Alberto
A1 González Bayón, Luis
AB Cisplatin is one of the most widely used chemotherapeutic agents in oncology, although its nephrotoxicity limits application and dosage. We present the results of a clinical study on prophylaxis of cisplatin-induced nephrotoxicity in patients with peritoneal carcinomatosis undergoing cytoreduction and hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC-cisplatin). Prophylaxis was with imipenem/cilastatin. Cilastatin is a selective inhibitor of renal dehydropeptidase I in the proximal renal tubule cells that can reduce the nephrotoxicity of cisplatin. Unfortunately, cilastatin is not currently marketed alone, and can only be administered in combination with imipenem. The study has a retrospective part that serves as a control (n = 99 patients receiving standard surgical prophylaxis) and a prospective part with imipenem/cilastatin prophylaxis corresponding to the study group (n = 85 patients). In both groups, we collected specific data on preoperative risk factors of renal damage, fluid management, hemodynamic control, and urine volume during surgery (including the hyperthermic chemotherapy perfusion), as well as data on hemodynamic and renal function during the first seven days after surgery. The main finding of the study is that cilastatin may exert a nephroprotective effect in patients with peritoneal carcinomatosis undergoing cytoreduction and hyperthermic intraperitoneal cisplatin perfusion. Creatinine values remained lower than in the control group (ANOVA test, p = 0.037). This translates into easier management of these patients in the postoperative period, with significantly shorter intensive care unit (ICU) and hospital stay.
PB MPDI
SN 1422-0067
YR 2021
FD 2021-01-27
LK https://hdl.handle.net/20.500.14352/7054
UL https://hdl.handle.net/20.500.14352/7054
LA eng
NO Zaballos M, Power M, Canal-Alonso MI, González-Nicolás MÁ, Vasquez-Jimenez W, Lozano-Lominchar P, et al. Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy. IJMS 2021;22:1239. https://doi.org/10.3390/ijms22031239.
NO Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional
NO Instituto de Salud Carlos III
NO Comunidad de Madrid
NO Fundación Senefro
NO Fundación Mutua Madrileña
DS Docta Complutense
RD 9 may 2025